More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$366928660
EPS
-2.01
P/E ratio
--
Price to sales
3.6
Dividend yield
--
Beta
0.969468
Previous close
$3.59
Today's open
$3.51
Day's range
$3.51 - $3.79
52 week range
$2.44 - $13.15
show more
CEO
Donn Casale
Employees
163
Headquarters
San Diego, CA
Exchange
NASDAQ Global Market
Shares outstanding
100528400
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
ARS Pharmaceuticals: Neffy Is Gaining Traction, But Revenue Growth Needs To Catch Up
ARS Pharmaceuticals remains a Hold into 1Q27; targeted commercial progress is encouraging, but stronger revenue growth and operating leverage need proof. Neffy demand rose 42%, but U.S. net product revenue grew just 7%; targeted-account share reached 9%, while gross-to-net remained around 50%. SPRY cut quarterly SG&A to $43.5 million and reaffirmed year-end 2027 cash flow breakeven, but liquidity fell to $138.4 million.
Seeking Alpha • 11 hours ago

ARS Pharmaceuticals Analysts Cut Their Forecasts After Downbeat Q3 Results
ARS Pharmaceuticals (NASDAQ:SPRY) on Thursday reported weaker-than-expected results for the third quarter.
Benzinga • Nov 6, 2026

ARS Pharmaceuticals, Inc. (SPRY) Q3 2026 Earnings Call Transcript
ARS Pharmaceuticals, Inc. ( SPRY ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Donn Casale - CEO, President & Director Meg Smith Kathleen Scott - Chief Financial Officer Conference Call Participants Monique Allaire - Thrust Strategic Communications Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Frank Wang Zhong - Leerink Partners LLC, Research Division Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division Presentation Operator Good afternoon, and welcome to ARS Pharma's Third Quarter 2026 Earnings Conference Call.
Seeking Alpha • Nov 6, 2026

ARS Pharmaceuticals Q3 Earnings Call Highlights
ARS Pharmaceuticals NASDAQ: SPRY reported $33.4 million in third-quarter U.S. net product revenue from its needle-free epinephrine treatment neffy and reaffirmed its goal of reaching cash flow breakeven by the end of 2027.
MarketBeat • Nov 6, 2026

ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Lags Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.52 per share a year ago.
Zacks Investment Research • Nov 5, 2026

ARS Pharmaceuticals: Lawsuits And Cash Burn Are Priced In, Yet The Stock Keeps Falling
ARS Pharmaceuticals is rated Buy, with current market pricing disconnected from fundamental pipeline value despite commercial setbacks. neffy, the flagship intranasal epinephrine spray, faces slow adoption and insurance hurdles but shows potential for significant market share and revenue. Management pivots to a leaner, targeted prescriber approach, aiming for late-2027 cash-flow breakeven while addressing heavy cash burn and term debt.
Seeking Alpha • Nov 3, 2026

ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
ARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Oct 29, 2026

ARS Pharma to Report Third Quarter 2026 Financial Results
SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions, today announced the company will host a conference call and webcast on Thursday, November 5, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to review its third quarter 2026 financial results.
GlobeNewsWire • Oct 28, 2026

SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
NEW YORK--(BUSINESS WIRE)---- $SPRY #ARS--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ARS Pharmaceuticals Inc. ("“ARS Pharmaceuticals” or the “Company”) (NASDAQ: SPRY) and reminds investors of the October 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California an.
Business Wire • Oct 5, 2026

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $SPRY--SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law.
Business Wire • Oct 5, 2026

¹ Disclosures

Open an M1 investment account to buy and sell ARS Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.